<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413916</url>
  </required_header>
  <id_info>
    <org_study_id>P20190104</org_study_id>
    <nct_id>NCT04413916</nct_id>
  </id_info>
  <brief_title>MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process</brief_title>
  <official_title>ASSOCIATION OF miRNA WITH ALLOGRAFT FUNCTION AND EXPRESSION PROFILES PREDICTIVE OF DISEASES OCCURING AFTER KIDNEY TRANSPLANTATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs (miRNAs) belong to a class of small non-coding RNAs that modulate physiological and&#xD;
      pathological processes by post-transcriptional regulation of gene expression mainly via&#xD;
      translational inhibition of target messenger RNAs. Recently, many miRNAs were found to be&#xD;
      involved in pathological processes that occur following kidney transplantation, like&#xD;
      allograft rejection, de novo disease or disease recurrence after kidney transplantation. As&#xD;
      most of the miRNAs involved in kidney diseases are extracted by urine, the diagnostic&#xD;
      accuracy of such molecules as biomarkers is questionable.&#xD;
&#xD;
      The aim of this study is to analyze expression of selected miRNAs (miR-29c, miR-126,&#xD;
      miR-146a, miR-150, miR-155, miR-223) and evaluate whether their regulation is associated with&#xD;
      kidney graft function and disease processes after kidney transplantation (KTx).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MicroRNAs (miRNA) are short, endogenous non-coding RNAs involved in the modulation of gene&#xD;
      expression mainly by inhibition of messenger RNAs translation. Recent studies have indicated&#xD;
      association of miRNAs with pathological processes following kidney transplantation.&#xD;
&#xD;
      The aim of the study is to determine whether selected miRNAs are related to specific disease&#xD;
      process or only reflect kidney graft function.&#xD;
&#xD;
      The study enrolled 100 Caucasian KTRs, who presented with stable renal function (as indicated&#xD;
      by stable serum creatinine (Cr) for 3 months and whose kidney graft function was thereafter&#xD;
      estimated with various methods, including: cystatin C concentration, three different CKD EPI&#xD;
      equations and measured with chromium-51 ethylenediamine tetraacetic acid clearance.&#xD;
&#xD;
      Expression of 6 selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, and miR-223)&#xD;
      was determined by qPCR using miRNA-103a, miR-191, and miR-423 as reference genes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of miRNA and kidney graft function</measure>
    <time_frame>sample collection within one month of enrollement</time_frame>
    <description>correlation of selected miRNAs expression with parameters of kidney graft function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of miRNAs expression and kidney graft rejection or disease recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of selected miRNAs expression and kidney graft rejection or disease recurrence</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Kidney Transplant Failure and Rejection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>miRNA expression</intervention_name>
    <description>Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serums from kidney transplant recipients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study included 100 kidney transplant recipients (KTRs) with at least 3 months of stable&#xD;
        kidney graft function established with estimated GFR (eGFR) according to CKD Epidemiology&#xD;
        Collaboration equations, serum creatinine concentration (CKD-EPI Cr), serum cystatin C&#xD;
        concentration (CKD-EPI CysC) and measured GFR with 51Cr-EDTA clearance.&#xD;
&#xD;
        Evaluation of kidney graft function was subject to previous, already completed, and&#xD;
        published study (Borštnar Š, et al. Clin Nephrol. 2019;92(6):287-292.&#xD;
        doi:10.5414/CN109882). Serum samples from patients participating in this study (taken at&#xD;
        the moment of 51Cr-EDTA clearance measurement) were further analyzed in the contemporary&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  time of kidney transplantation at least 2 years before the study entry,&#xD;
&#xD;
          -  stable function of the transplanted kidney during the previous 3 months (changes in&#xD;
             s-creatinine ≤ 20%).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  age less than 18 years,&#xD;
&#xD;
          -  symptomatic heart failure,&#xD;
&#xD;
          -  malignancy,&#xD;
&#xD;
          -  pregnancy or lactation,&#xD;
&#xD;
          -  acute conditions and diseases that can affect the GFR,&#xD;
&#xD;
          -  newly-introduced drugs that may affect the function of the graft,&#xD;
&#xD;
          -  treatment with trimethoprim-sulfamethoxazole or cimetidine,&#xD;
&#xD;
          -  the presence of a pacemaker or any other electronic device in the body.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Veceric-Haler Zeljka</investigator_full_name>
    <investigator_title>assist. prof.</investigator_title>
  </responsible_party>
  <keyword>miRNA</keyword>
  <keyword>kidney transplant function</keyword>
  <keyword>kidney transplant rejection</keyword>
  <keyword>disease recurrence</keyword>
  <keyword>cystatin</keyword>
  <keyword>micro RNA</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

